Neumora Therapeutic NMRA 深 滬
等待開盤 04-03 09:30:00 美东时间
2.00
-0.090
-4.31%
華盛通- 最 高2.105
- 今 開2.06
- 成交量 123.82万股
- 最 低 1.98
- 昨 收 2.09
- 總市值 3.64亿
- 52周最高 3.65
- 市盈率 靜 --
- 換手率 0.68%
- 52周最低 0.611
- 委 比 69.04%
- 總股本 1.82亿
- 歷史最高 21.00
- 量 比 0.64
- 振 幅 5.98%
- 歷史最低 0.611
- 每 手 1
- 風險率 0.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Neumora Therapeutics Q4 EPS $(0.35) Misses $(0.33) Estimate
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 7.36 percent. This is a 5.41 percent increase over losses of $(0.37) per share
03-30 19:21
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
Neumora FY25 net loss narrows to $237 million; cash drops to $183 million
Neumora FY25 net loss narrows to $237 million; cash drops to $183 million Neumora posted a Q4 net loss of USD 59 million, with loss per share at USD 0.35. Full-year net loss narrowed to USD 237 million, with loss per share improving to USD 1.45. Operating loss widened to USD 241 million as R&D spend
03-30 18:53
Neumora Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Neumora Therapeutics, Inc. (NASDAQ:NMRA) will release earnings for the fourth q...
03-28 00:26
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
Neumora Therapeutics announced it will host a conference call and live webcast on March 30, 2026, at 8:00 a.m. ET to discuss its fourth quarter and full year 2025 financial results and provide a business update. A live webcast will be available on the Company’s website, www.neumoratx.com, with a replay archived for 30 days. Participants can register here. Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing nov...
03-16 11:00
LB Pharmaceuticals appoints Robert Lenz to board
LB Pharmaceuticals appoints Robert Lenz to board LB Pharmaceuticals appointed Robert Lenz, M.D., Ph.D. to its board of directors. Lenz most recently served as executive vice president and head of R&D at Neumora Therapeutics. Disclaimer: This news brief was created by Public Technologies (PUBT) using
03-09 20:01
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
LB Pharmaceuticals announces the appointment of Dr. Robert Lenz, a veteran neuroscientist with over 20 years of experience in drug development, to its Board of Directors. His expertise is expected to support the advancement of LB-102, a promising investigational therapy for neuropsychiatric disorders. Dr. Lenz brings extensive leadership experience from roles at major pharmaceutical companies, including Amgen and Neumora Therapeutics, where he ov...
03-09 12:00
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment
William Blair upgrades Neumora after strong Alzheimer's agitation data, sees upside from NMRA-511 and obesity pipeline potential.
02-18 03:32
William Blair Upgrades Neumora Therapeutics to Outperform
William Blair analyst Myles Minter upgrades Neumora Therapeutics (NASDAQ:NMRA) from Market Perform to Outperform.
02-17 23:21
